4571
Nano Holdings,Inc.
ＮＡＮＯホールディングス
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Notes
- Consolidation basisConsolidated / Since Mar 2023
Key metrics
Revenue(thousand JPY)
Mar 2022
264,032
Mar 2023
202,189
Mar 2024
135,508
Mar 2025
108,516
Mar 2026
174,498
Operating profit(thousand JPY)
Mar 2022
-2,061,088
Mar 2023
-1,246,000
Mar 2024
-864,415
Mar 2025
-755,349
Mar 2026
-965,988
Operating profit margin(%)
Mar 2022
-780.62
Mar 2023
-616.26
Mar 2024
-637.91
Mar 2025
-696.07
Mar 2026
-553.58
Profit before tax(thousand JPY)
Mar 2022
-1,879,056
Mar 2023
-1,308,486
Mar 2024
-777,512
Mar 2025
-832,594
Mar 2026
-940,753
Profit(thousand JPY)
Mar 2022
-1,881,678
Mar 2023
-1,310,976
Mar 2024
-780,002
Mar 2025
-835,380
Mar 2026
-943,880
Total assets(thousand JPY)
Mar 2022
7,136,247
Mar 2023
5,784,390
Mar 2024
5,071,279
Mar 2025
3,996,884
Mar 2026
5,906,339
Cash and cash equivalents(thousand JPY)
Mar 2022
1,097,044
Mar 2023
1,309,592
Mar 2024
1,575,263
Mar 2025
1,197,201
Mar 2026
4,910,354
Cash flows from operating activities(thousand JPY)
Mar 2022
-1,752,992
Mar 2023
-1,087,051
Mar 2024
-585,081
Mar 2025
-401,617
Mar 2026
-816,672
Cash flows from investing activities(thousand JPY)
Mar 2022
-244,133
Mar 2023
1,207,913
Mar 2024
793,007
Mar 2025
587,528
Mar 2026
2,261,576
Cash flows from financing activities(thousand JPY)
Mar 2022
1,145,835
Mar 2023
-
Mar 2024
3,728
Mar 2025
-568,775
Mar 2026
2,222,415
Return on equity(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Equity ratio(%)
Mar 2022
77.6
Mar 2023
73.5
Mar 2024
67.2
Mar 2025
68.2
Mar 2026
59.9
Earnings per share(JPY per share)
Mar 2022
-26.9
Mar 2023
-18.7
Mar 2024
-11.1
Mar 2025
-11.85
Mar 2026
-12.9
Net assets per share(JPY per share)
Mar 2022
79.08
Mar 2023
60.61
Mar 2024
48.39
Mar 2025
38.59
Mar 2026
43.11
Dividend per share(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Payout ratio(-)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.